View Future GrowthTechno Drugs 過去の業績過去 基準チェック /16Techno Drugsの収益は年間平均-21.4%の割合で減少していますが、 Pharmaceuticals業界の収益は年間 増加しています。収益は年間5.8% 2.6%割合で 増加しています。 Techno Drugsの自己資本利益率は4.9%であり、純利益率は6.5%です。主要情報-21.44%収益成長率-34.85%EPS成長率Pharmaceuticals 業界の成長11.00%収益成長率2.58%株主資本利益率4.89%ネット・マージン6.53%前回の決算情報31 Mar 2026最近の業績更新お知らせ • Apr 27Techno Drugs Ltd. to Report Q3, 2026 Results on Apr 29, 2026Techno Drugs Ltd. announced that they will report Q3, 2026 results on Apr 29, 2026お知らせ • Jan 29Techno Drugs Ltd. to Report Q2, 2026 Results on Jan 31, 2026Techno Drugs Ltd. announced that they will report Q2, 2026 results on Jan 31, 2026お知らせ • Nov 09Techno Drugs Ltd. to Report Q1, 2026 Results on Nov 13, 2025Techno Drugs Ltd. announced that they will report Q1, 2026 results on Nov 13, 2025お知らせ • Oct 21Techno Drugs Ltd. to Report Fiscal Year 2025 Results on Oct 28, 2025Techno Drugs Ltd. announced that they will report fiscal year 2025 results on Oct 28, 2025お知らせ • Apr 23Techno Drugs Ltd. to Report Q3, 2025 Results on Apr 29, 2025Techno Drugs Ltd. announced that they will report Q3, 2025 results on Apr 29, 2025お知らせ • Jan 27Techno Drugs Ltd. to Report Q2, 2025 Results on Jan 30, 2025Techno Drugs Ltd. announced that they will report Q2, 2025 results on Jan 30, 2025すべての更新を表示Recent updatesBoard Change • May 20Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 5 non-independent directors. Independent Director SK. Rahman was the last independent director to join the board, commencing their role in 2023. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.お知らせ • Apr 27Techno Drugs Ltd. to Report Q3, 2026 Results on Apr 29, 2026Techno Drugs Ltd. announced that they will report Q3, 2026 results on Apr 29, 2026お知らせ • Jan 29Techno Drugs Ltd. to Report Q2, 2026 Results on Jan 31, 2026Techno Drugs Ltd. announced that they will report Q2, 2026 results on Jan 31, 2026お知らせ • Nov 09Techno Drugs Ltd. to Report Q1, 2026 Results on Nov 13, 2025Techno Drugs Ltd. announced that they will report Q1, 2026 results on Nov 13, 2025お知らせ • Oct 30Techno Drugs Ltd. announces Annual dividend, payable on January 25, 2026Techno Drugs Ltd. announced Annual dividend of BDT 1.0000 per share payable on January 25, 2026, ex-date on November 20, 2025 and record date on November 19, 2025.お知らせ • Oct 29Techno Drugs Ltd., Annual General Meeting, Dec 24, 2025Techno Drugs Ltd., Annual General Meeting, Dec 24, 2025, at 10:00 Central Asia Standard Time. Location: hybrid system in combination of physical, presence at institution of diploma engineers, l60/a, kakrail vip road, through the link., Bangladeshお知らせ • Oct 21Techno Drugs Ltd. to Report Fiscal Year 2025 Results on Oct 28, 2025Techno Drugs Ltd. announced that they will report fiscal year 2025 results on Oct 28, 2025お知らせ • Apr 23Techno Drugs Ltd. to Report Q3, 2025 Results on Apr 29, 2025Techno Drugs Ltd. announced that they will report Q3, 2025 results on Apr 29, 2025お知らせ • Jan 27Techno Drugs Ltd. to Report Q2, 2025 Results on Jan 30, 2025Techno Drugs Ltd. announced that they will report Q2, 2025 results on Jan 30, 2025お知らせ • Nov 11Techno Drugs Ltd. to Report Q1, 2025 Results on Nov 14, 2024Techno Drugs Ltd. announced that they will report Q1, 2025 results on Nov 14, 2024お知らせ • Oct 29Techno Drugs Ltd. Recommends 12% Cash Dividend for the year ended June 30, 2024The Board of Directors of Techno Drugs Ltd. recommended 12% Cash Dividend only for general shareholders other than Board of Directors for the year ended June 30, 2024. Directors/sponsor are holding 82,776,200 shares and General Public are holding 49,221,988 shares. Cash dividend payable to General Public is Tk. 59,066,386.00. Date of AGM: December 26, 2024.Valuation Update With 7 Day Price Move • Oct 24Investor sentiment deteriorates as stock falls 17%After last week's 17% share price decline to ৳38.00, the stock trades at a trailing P/E ratio of 25.3x. Average trailing P/E is 18x in the Pharmaceuticals industry in Bangladesh.お知らせ • Oct 22Techno Drugs Ltd. to Report Fiscal Year 2024 Results on Oct 27, 2024Techno Drugs Ltd. announced that they will report fiscal year 2024 results on Oct 27, 2024New Risk • Sep 27New major risk - Financial data availabilityThe company's latest financial reports are more than a year old. Last reported fiscal period ended June 2023. This is considered a major risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. In the worst case scenario, it may be facing other major going concern issues jeopardizing its viability as a listed company. Currently, the following risks have been identified for the company: Major Risks Latest financial reports are more than 1 year old (reported June 2023 fiscal period end). Interest payments are not well covered by earnings (2.0x net interest cover). Share price has been highly volatile over the past 3 months (12% average weekly change). Revenue has declined by 46% over the past year. Minor Risk Market cap is less than US$100m (৳5.87b market cap, or US$49.0m).Valuation Update With 7 Day Price Move • Sep 08Investor sentiment deteriorates as stock falls 19%After last week's 19% share price decline to ৳40.50, the stock trades at a trailing P/E ratio of 27x. Average trailing P/E is 24x in the Pharmaceuticals industry in Bangladesh.Board Change • Jul 14Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 5 non-independent directors. Independent Director SK. Rahman was the last independent director to join the board, commencing their role in 2023. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.収支内訳Techno Drugs の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。収益と収入の歴史DSE:TECHNODRUG 収益、費用、利益 ( )BDT Millions日付収益収益G+A経費研究開発費31 Mar 263,102202664031 Dec 253,150206679030 Sep 253,233216708030 Jun 253,376232759031 Mar 253,127223720031 Dec 242,993219711030 Sep 243,176256737030 Jun 243,613281848030 Jun 232,733196628030 Jun 225,0294809050質の高い収益: TECHNODRUGは 高品質の収益 を持っています。利益率の向上: TECHNODRUGの現在の純利益率 (6.5%)は、昨年(7.1%)よりも低くなっています。フリー・キャッシュフローと収益の比較過去の収益成長分析収益動向: TECHNODRUGの収益は過去 5 年間で年間21.4%減少しました。成長の加速: TECHNODRUGは過去 1 年間の収益成長がマイナスであったため、5 年間の平均と比較することはできません。収益対業界: TECHNODRUGは過去 1 年間で収益成長率がマイナス ( -9.1% ) となったため、 Pharmaceuticals業界平均 ( 10.5% ) と比較することが困難です。株主資本利益率高いROE: TECHNODRUGの 自己資本利益率 ( 4.9% ) は 低い とみなされます。総資産利益率使用総資本利益率過去の好業績企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 、過去の業績が好調な企業。View Financial Health企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/07/14 18:15終値2026/07/14 00:00収益2026/03/31年間収益2025/06/30データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Techno Drugs Ltd. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
お知らせ • Apr 27Techno Drugs Ltd. to Report Q3, 2026 Results on Apr 29, 2026Techno Drugs Ltd. announced that they will report Q3, 2026 results on Apr 29, 2026
お知らせ • Jan 29Techno Drugs Ltd. to Report Q2, 2026 Results on Jan 31, 2026Techno Drugs Ltd. announced that they will report Q2, 2026 results on Jan 31, 2026
お知らせ • Nov 09Techno Drugs Ltd. to Report Q1, 2026 Results on Nov 13, 2025Techno Drugs Ltd. announced that they will report Q1, 2026 results on Nov 13, 2025
お知らせ • Oct 21Techno Drugs Ltd. to Report Fiscal Year 2025 Results on Oct 28, 2025Techno Drugs Ltd. announced that they will report fiscal year 2025 results on Oct 28, 2025
お知らせ • Apr 23Techno Drugs Ltd. to Report Q3, 2025 Results on Apr 29, 2025Techno Drugs Ltd. announced that they will report Q3, 2025 results on Apr 29, 2025
お知らせ • Jan 27Techno Drugs Ltd. to Report Q2, 2025 Results on Jan 30, 2025Techno Drugs Ltd. announced that they will report Q2, 2025 results on Jan 30, 2025
Board Change • May 20Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 5 non-independent directors. Independent Director SK. Rahman was the last independent director to join the board, commencing their role in 2023. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
お知らせ • Apr 27Techno Drugs Ltd. to Report Q3, 2026 Results on Apr 29, 2026Techno Drugs Ltd. announced that they will report Q3, 2026 results on Apr 29, 2026
お知らせ • Jan 29Techno Drugs Ltd. to Report Q2, 2026 Results on Jan 31, 2026Techno Drugs Ltd. announced that they will report Q2, 2026 results on Jan 31, 2026
お知らせ • Nov 09Techno Drugs Ltd. to Report Q1, 2026 Results on Nov 13, 2025Techno Drugs Ltd. announced that they will report Q1, 2026 results on Nov 13, 2025
お知らせ • Oct 30Techno Drugs Ltd. announces Annual dividend, payable on January 25, 2026Techno Drugs Ltd. announced Annual dividend of BDT 1.0000 per share payable on January 25, 2026, ex-date on November 20, 2025 and record date on November 19, 2025.
お知らせ • Oct 29Techno Drugs Ltd., Annual General Meeting, Dec 24, 2025Techno Drugs Ltd., Annual General Meeting, Dec 24, 2025, at 10:00 Central Asia Standard Time. Location: hybrid system in combination of physical, presence at institution of diploma engineers, l60/a, kakrail vip road, through the link., Bangladesh
お知らせ • Oct 21Techno Drugs Ltd. to Report Fiscal Year 2025 Results on Oct 28, 2025Techno Drugs Ltd. announced that they will report fiscal year 2025 results on Oct 28, 2025
お知らせ • Apr 23Techno Drugs Ltd. to Report Q3, 2025 Results on Apr 29, 2025Techno Drugs Ltd. announced that they will report Q3, 2025 results on Apr 29, 2025
お知らせ • Jan 27Techno Drugs Ltd. to Report Q2, 2025 Results on Jan 30, 2025Techno Drugs Ltd. announced that they will report Q2, 2025 results on Jan 30, 2025
お知らせ • Nov 11Techno Drugs Ltd. to Report Q1, 2025 Results on Nov 14, 2024Techno Drugs Ltd. announced that they will report Q1, 2025 results on Nov 14, 2024
お知らせ • Oct 29Techno Drugs Ltd. Recommends 12% Cash Dividend for the year ended June 30, 2024The Board of Directors of Techno Drugs Ltd. recommended 12% Cash Dividend only for general shareholders other than Board of Directors for the year ended June 30, 2024. Directors/sponsor are holding 82,776,200 shares and General Public are holding 49,221,988 shares. Cash dividend payable to General Public is Tk. 59,066,386.00. Date of AGM: December 26, 2024.
Valuation Update With 7 Day Price Move • Oct 24Investor sentiment deteriorates as stock falls 17%After last week's 17% share price decline to ৳38.00, the stock trades at a trailing P/E ratio of 25.3x. Average trailing P/E is 18x in the Pharmaceuticals industry in Bangladesh.
お知らせ • Oct 22Techno Drugs Ltd. to Report Fiscal Year 2024 Results on Oct 27, 2024Techno Drugs Ltd. announced that they will report fiscal year 2024 results on Oct 27, 2024
New Risk • Sep 27New major risk - Financial data availabilityThe company's latest financial reports are more than a year old. Last reported fiscal period ended June 2023. This is considered a major risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. In the worst case scenario, it may be facing other major going concern issues jeopardizing its viability as a listed company. Currently, the following risks have been identified for the company: Major Risks Latest financial reports are more than 1 year old (reported June 2023 fiscal period end). Interest payments are not well covered by earnings (2.0x net interest cover). Share price has been highly volatile over the past 3 months (12% average weekly change). Revenue has declined by 46% over the past year. Minor Risk Market cap is less than US$100m (৳5.87b market cap, or US$49.0m).
Valuation Update With 7 Day Price Move • Sep 08Investor sentiment deteriorates as stock falls 19%After last week's 19% share price decline to ৳40.50, the stock trades at a trailing P/E ratio of 27x. Average trailing P/E is 24x in the Pharmaceuticals industry in Bangladesh.
Board Change • Jul 14Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 5 non-independent directors. Independent Director SK. Rahman was the last independent director to join the board, commencing their role in 2023. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.